KP-496

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2010
0120062010

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Cysteinyl-leukotrienes (cysLTs) and thromboxane A(2) (TXA(2)) are important mediators in inflammatory lung diseases such as… (More)
Is this relevant?
2009
2009
Bronchial asthma is characterized by chronic airway inflammation. Eosinophils are involved in airway inflammation and play… (More)
Is this relevant?
2009
2009
AIMS The aim of this study was to evaluate the effects of inhaled KP-496, a novel dual antagonist for cysteinyl leukotriene… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2008
2008
BACKGROUND AND PURPOSE KP-496 is a novel dual antagonist for cysteinyl leukotriene receptor 1 (CysLT(1)) and thromboxane A(2… (More)
Is this relevant?
2007
2007
KP-496 is a novel dual antagonist for leukotriene (LT) D4 and thromboxane (TX) A2 receptors. We investigated effects of KP-496 on… (More)
  • figure 1
  • figure 2
  • table 1
  • table 3
  • table 2
Is this relevant?
2006
2006
BACKGROUND A dry powder inhaler of KP-496 is currently in clinical development in Japan as an anti-asthmatic agent. The aim of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?